Sophia Genetics SAS
SOPHiA GENETICS is dedicated to transforming patient care through data-driven medicine by providing AI-powered, cloud-based solutions that analyze complex health data. Their platform, SOPHiA DDM™, connects a global network of healthcare institutions to deliver actionable insights for cancer, rare disorders, inherited diseases, and more, aiming to democratize access to precision medicine worldwide. The company offers solutions for genomics, radiomics, multimodal data analysis, and specialized applications such as hereditary cancer, blood cancers, solid tumors, and pharmacogenetics, supporting research and clinical workflows globally.
Industries
Nr. of Employees
large (251-1000)
Sophia Genetics SAS
Boston, Massachusetts, United States, North America
Products
Cloud-based analytics platform for multimodal precision medicine
Cloud-native analytics platform that standardizes, analyzes and interprets genomic, imaging and clinical data using AI/ML to produce clinical and research insights.
NGS-based genomics applications for oncology and inherited disorders
Validated NGS applications and workflows for comprehensive genomic profiling, homologous recombination deficiency analysis, myeloid panels, hereditary cancer testing and liquid biopsy use cases.
Cloud-based analytics platform for multimodal precision medicine
Cloud-native analytics platform that standardizes, analyzes and interprets genomic, imaging and clinical data using AI/ML to produce clinical and research insights.
NGS-based genomics applications for oncology and inherited disorders
Validated NGS applications and workflows for comprehensive genomic profiling, homologous recombination deficiency analysis, myeloid panels, hereditary cancer testing and liquid biopsy use cases.
Services
NGS clinical trial assay (CTA) co-development
Design and optimize NGS-based assays and algorithms for use in clinical trials, including analytical validation and implementation guidance.
Companion diagnostic (CDx) development and regulatory support
End-to-end support for development, regulatory submission planning, and commercialization of NGS-based companion diagnostics.
Multimodal AI data analytics and modeling
Machine learning services that integrate genomic, imaging and clinical data to identify predictive signatures, perform patient stratification and support market access strategies.
Professional services: implementation, training and sponsored testing
On-site consultation, hands-on training, workflow optimization, sponsored testing programs and post-commercial adoption support to enable local testing capabilities.
Clinical trial enrollment acceleration (trial matching)
Services and tooling to accelerate patient identification and enrollment by matching patient molecular profiles to relevant clinical trials.
NGS clinical trial assay (CTA) co-development
Design and optimize NGS-based assays and algorithms for use in clinical trials, including analytical validation and implementation guidance.
Companion diagnostic (CDx) development and regulatory support
End-to-end support for development, regulatory submission planning, and commercialization of NGS-based companion diagnostics.
Multimodal AI data analytics and modeling
Machine learning services that integrate genomic, imaging and clinical data to identify predictive signatures, perform patient stratification and support market access strategies.
Professional services: implementation, training and sponsored testing
On-site consultation, hands-on training, workflow optimization, sponsored testing programs and post-commercial adoption support to enable local testing capabilities.
Clinical trial enrollment acceleration (trial matching)
Services and tooling to accelerate patient identification and enrollment by matching patient molecular profiles to relevant clinical trials.
Expertise Areas
- Multimodal AI-driven analytics
- Decentralized genomics networks and deployment
- NGS data analysis and variant interpretation
- Liquid biopsy and cfDNA longitudinal monitoring
Key Technologies
- Next-generation sequencing (NGS)
- Cell-free DNA (cfDNA) / liquid biopsy
- RNA-based and DNA-based fusion detection
- Low-pass whole genome sequencing (lpWGS) for HRD